Business
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of
About this update from Artiva Biotherapeutics, Inc.
[{"type":"image","alt":"Artiva Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Artiva Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":163,"url":"https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EzrD6_Mjfgj__sILFOHDTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyOA--/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EzrD6_Mjfgj__sILFOHDTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyOA--/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.","length":434,"tagName":"p"},{"type":"text","content":"To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.","length":251,"tagName":"p"},{"type":"text","content":"About Artiva BiotherapeuticsArtiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune dise...